Onco Actu du 12 octobre 2017

	1. Biologie
NIH completes atlas of human DNA differences that influence gene expression [NIH] The atlas is the culmination of work from the Genotype-Tissue Expression (GTEx) Consortium, established to catalog how genomic variation influences how genes are turned off and on.
	3.2 Prévention - Obésité
The second biggest preventable cause of cancer: being overweight [Cancer Research UK] Very few studies have looked at whether cancer risk decreases after someone loses weight.
	4. Dépistage, diagnostic et pronostic
Severe shortage of radiologists risks delays to cancer diagnosis, says report [Cancer Research UK] The report shows that while the consultant radiology workforce has increased by 3% since 2010, this hasn’t kept pace with increased demand placed on radiology services.
	4.2 Dép., diag. & prono. - Génome
The future of DNA sequencing [Nature] Eric D. Green, Edward M. Rubin and Maynard V. Olson speculate on the next forty years of the applications, from policing to data storage.
The rise and fall and rise again of 23andMe [Nature] Most scientists no longer see 23andme as a frivolous undertaking. The ability to recruit two million customers, and potentially many more, has been a huge draw, and researchers are lining up to collaborate with the company.
	4.7 Dép., diag. & prono. - Col de l'utérus
Could Making Cancer Screening Simpler Increase Women's Risk? [NPR] A proposal to simplify cervical cancer screening could end up missing some cancers, researchers and patient advocates say. And that could be especially true for minority women.
	5. Traitements
Seattle Biotech Blaze Bioscience Adds $16M for Clinical Trial Work [Xconomy] Blaze Bioscience, a Seattle-based biotech that’s developing “tumor paint” to help surgeons differentiate healthy tissue from tumors that should be removed, has raised a $16.1 million Series B-1 round of funding from existing investors.
	5.12.2 Immunothérapies - CAR-T
Mustang CAR-T brain tumor trial gets funds to expand [FierceBiotech] The $12.8 million grant equips the team to expand arms that are assessing different routes of administration of the IL13Rα2‐specific autologous CAR-T cells.
	5.2 Pharma
U.S. FDA Grants Fast Track Designation to Astellas for Development of Gilteritinib in Relapsed or Refractory Acute Myeloid Leukemia [Astellas] Gilteritinib is an investigational compound that has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD) as well as FLT3 tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in approximately one-third of patients with AML.
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer [janssen] First Agent Submitted to Address a Critical Need in Earlier Stage Castration-Resistant Prostate Cancer at High-Risk for Metastasis.
	5.3 Traitements - FDA, EMA, NICE...
Statement by FDA Commissioner Scott Gottlieb, M.D. on new steps by FDA to advance patient engagement in the agency’s regulatory work [FDA] This is the agency’s first advisory committee that’s comprised solely of patients, care-partners, and those who represent their needs.
	5.4 Traitements - Economie
New treatment option for people with gastrointestinal cancer [NICE] Evidence reviewed by the NICE appraisal committee showed regorafenib can extend a GIST patient’s life by more than nine months compared to ‘best supportive care’; the alternative treatment for people with this type of progressive cancer.
NICE backing for Bayer’s Stivarga in GIST [PharmaTimes] Stivarga (regorafenib) has been available for patients with GIST - a common type of sarcoma arising from the muscle wall of the gastrointestinal tract - on the Cancer Drugs Fund since 2013, but with this latest decision will switch into the NHS’ normal commissioning stream.
	6. Lutte contre les cancers
‘We have entered a new era’: Cancer researchers no longer follow a single path to discovery [STAT] Blocking tumor progression. Developing liquid biopsies. Engaging patients to find personalized treatments. They are all tantalizing ways in which scientists hope to make progress against cancer, a panel of experts noted Wednesday, even as steep challenges remain and the conversation around treatment evolves.
Last Month in Oncology with Dr. Bishal Gyawali: September 2017 [ecancernews] Is nivolumab ipilimumab better than nivolumab? Well, we didn’t test that.
Why is so hard do cure Cancer? [TEDEd] We’ve harnessed electricity, sequenced the human genome, and eradicated smallpox. But after billions of dollars in research, we haven’t found a solution for a disease that affects more than 14 million people and their families at any given time. Why is it so difficult to cure cancer? Kyuson Yun explains the challenges.
	6.10 Politiques
Medicines research warning over Brexit [BBC News] Britain risks losing its leading position in drug research and development if plans for regulating medicines after Brexit are not set out soon, one of the UK's most influential research leaders has warned.
	6.11 Patients
Prostate cancer patients unclear on differences among treatments [Reuters] Patients who spoke to a nurse specialist or radiotherapist in addition to the urologist had a better understanding of the differences between treatments. “This finding encourages the incorporation of a nurse specialist and/or multidisciplinary consults in routine care,” Van Stam said.
	6.6 Publications
A journal printed a sharp critique of a paper it had published. If only it had checked with the authors first. [Retraction Watch] In 2016, researchers published a paper showing that an RNA molecule may be overactive in breast tumor tissue. But after reading the paper, three biologists believed the data supported the opposite conclusion. What happened after that is a tale of misunderstandings and unnecessarily bruised feelings.